Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "United States Protein Labeling - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
United States Protein Labeling Market to Reach USD 1.96 Billion by 2031 as Proteomics and Cell-Based Research Expand
The United States protein labeling market was valued at USD 1.20 billion in 2025 and is projected to increase from USD 1.30 billion in 2026 to USD 1.96 billion by 2031. The market is expected to register a compound annual growth rate of 8.52% during the 2026-2031 forecast period, supported by expanding proteomics research, targeted drug development, advanced cell-based assays, and demand for site-specific labeling technologies.
Proteomics and Multi-Omics Programs Accelerate Market Growth
The expansion of large-scale proteomics and multi-omics research is strengthening demand across the United States protein labeling market. Population-scale protein profiling is becoming increasingly practical within translational research programs, creating greater need for labeling reagents, affinity enrichment materials, biotinylated probes, crosslinkers, and mass spectrometry tags.
UltraPlex-TMT, published in 2026, supports 58-plex pseudo-multiplexed analysis using orthogonal protease digestion. This approach increases the number of samples that can be processed in a single liquid chromatography-mass spectrometry run without requiring additional instrumentation. Higher throughput is expected to increase reagent consumption as laboratories label and analyze more samples within shorter research cycles.
Multi-omics programs are also raising demand for compatible and orthogonal chemistries across proteomic, genomic, and metabolomic workflows. Thermo Fisher Scientific's 2026 launch of the Orbitrap Tribrid Apex, featuring AI-enabled software for large-scale proteomic data analysis, further highlights the growing importance of high-purity protein labeling reagents in advanced research environments.
ADC Development and Targeted Protein Degradation Create New Demand
Antibody-drug conjugate development is transforming protein labeling from a routine analytical procedure into a precision-focused requirement. Drug-to-antibody ratio control and conjugation-site definition have become increasingly important in regulated development, encouraging the adoption of site-specific conjugation methods over random-labeling chemistries.
In February 2026, Lonza integrated GlycoConnect, HydraSpace, and toxSYN into its Advanced Synthesis platform and expanded the offering to include dual-payload antibody-drug conjugate formats. This development reflects the growing need for precisely controlled conjugation technologies in next-generation therapeutics.
Targeted protein degradation is generating additional demand because researchers must label E3 ligase-recruiting and target-binding components to verify cellular engagement. Individual development programs may require site-specific conjugation kits, fluorescent probes, and mass-tag quantification reagents simultaneously, supporting recurring procurement and long-term supplier relationships.
High Workflow Costs Remain a Market Restraint
Despite strong growth prospects, the high cost of quantitative proteomics continues to limit adoption among academic institutions and clinical laboratories. High-resolution Orbitrap and time-of-flight instruments can cost between USD 500,000 and USD 1.5 million per unit. Deployment also requires premium labeling kits, chromatography systems, specialized software, and trained bioinformatics personnel.
These costs encourage some laboratories to continue using established western blot and ELISA workflows. Premium multiplex tag kits also add substantial per-experiment expenses, potentially reducing testing frequency. Limited access to bioinformatics expertise presents a further challenge, particularly when laboratories must interpret complex data-independent acquisition outputs. Additional market influences include increased outsourcing of conjugation services to CROs and CDMOs, growing adoption of bioorthogonal labeling, and regulatory complexity surrounding radioisotope conjugates.
Reagents and Kits Maintain Market Leadership
Reagents and kits accounted for 70.31% of the United States protein labeling market in 2025. Their leading position reflects widespread use in immunoassays, proteomics platforms, biopharmaceutical quality control, and standardized laboratory protocols. Demand remains strong for fluorescent dyes, biotin capture systems, and mass-tag kits that help laboratories maintain reliable and reproducible results.
Services are forecast to record a 10.38% CAGR through 2031, making them the fastest-growing product segment. As site-specific and bioorthogonal labeling methods become more technically demanding, pharmaceutical and biotechnology organizations are increasingly outsourcing custom conjugation work. GenScript's May 2026 launch of the TurboCHO Protein Expression Kit, offering output within three to five days and yields reportedly up to five times higher than competing formats, illustrates the growing emphasis on faster outsourced research workflows.
Cell-Based Assays Set to Record the Fastest Application Growth
Immunological techniques represented 34.24% of the United States protein labeling market in 2025. ELISA, western blot, and immunohistochemistry remain widely used across laboratory procedures, pathology workflows, and lot-release testing. Their established role within standard operating procedures is expected to support continued demand.
Cell-based assays are projected to grow at a 10.52% CAGR through 2031, the fastest rate among application categories. Growth is being driven by live-cell research, protein interaction studies, three-dimensional cell models, and organoid-based testing. Merck and Promega have combined Duolink proximity ligation assay technology with HiBiT split-luciferase reporters to support protein-interaction detection and target-level quantification in 3D cell models. These advances are expanding demand for cell-permeant probes, enzymatic tags, and volumetric labeling technologies, reinforcing the positive outlook for the United States protein labeling market through 2031.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expansion of proteomics and multi-omics pipelines
4.2.2 Growing use in ADC and targeted protein degradation workflows
4.2.3 Rising outsourcing of complex conjugation to CROs and CDMOs
4.2.4 Shift toward site-specific and bioorthogonal labeling
4.2.5 AI-assisted probe design for multiplex imaging
4.2.6 Single-day organ-scale in-tissue labeling platforms
4.3 Market Restraints
4.3.1 High cost of high-resolution mass spectrometry workflows
4.3.2 Regulatory complexity for radio-isotope conjugates
4.3.3 Dye stability and cold-chain burden
4.3.4 Large-tag steric hindrance and localization artifacts
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product
5.1.1 Reagents and Kits
5.1.2 Services
5.1.3 Consumables
5.2 By Application
5.2.1 Immunological Techniques
5.2.2 Cell-based Assays
5.2.3 Fluorescence Microscopy
5.2.4 Protein Microarrays
5.2.5 Mass Spectrometry
5.3 By Labeling Method
5.3.1 In-vitro Labeling
5.3.2 In-vivo Labeling
5.4 By End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Contract Research and Development / Manufacturing Organizations
5.4.3 Academic and Research Institutes
5.4.4 Clinical Diagnostics Laboratories
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Abcam plc
6.3.2 Agilent Technologies Inc.
6.3.3 Bio-Rad Laboratories Inc.
6.3.4 Bio-Techne Corporation
6.3.5 Biotium Inc.
6.3.6 Cell Signaling Technology
6.3.7 Creative Diagnostics
6.3.8 Danaher Corporation
6.3.9 F. Hoffmann-La Roche Ltd.
6.3.10 GenScript Biotech Corporation
6.3.11 LI-COR Biosciences
6.3.12 Lonza Group AG
6.3.13 Lumiprobe Corporation
6.3.14 Merck KGaA
6.3.15 New England Biolabs Inc.
6.3.16 Promega Corporation
6.3.17 Proteintech Group
6.3.18 Revvity Inc.
6.3.19 Sartorius AG
6.3.20 Takara Bio Inc.
6.3.21 Thermo Fisher Scientific Inc.
6.3.22 Vector Laboratories Inc.
6.3.23 WuXi Biologics
7 Market Opportunities & Future Outlook
7.1 White-space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/moylo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
